comparemela.com

Latest Breaking News On - புற்றுநோய் ஆராய்ச்சி குழு - Page 2 : comparemela.com

New Method to Combat Metastatic Melanoma Identified

New Method to Combat Metastatic Melanoma Identified
medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.

Analysis reveals origins of a leukemia that straddles diagnostic categories

Analysis reveals origins of a leukemia that straddles diagnostic categories
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

ECOG-ACRIN research highlights at ASCO 2021

 E-Mail New research results for patients with breast and HPV-associated throat cancers are the highlights among 23 presentations by ECOG-ACRIN Cancer Research Group researchers at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, occurring virtually June 4-8. The National Cancer Institute (NCI), part of the National Institutes of Health, funded these studies. Breast Cancer Platinum chemotherapy fails in phase III trial for triple-negative breast cancer, basal-like subtype Abstract 605: About 80% of triple-negative breast cancers (TNBC) are a subtype called basal-like. Typically, patients with TNBC receive chemotherapy before surgery to shrink the tumor(s). The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will progress after surgery. A previous clinical trial demonstrated that additional capecitabine chemotherapy after surgery helps decrease the chance of recurrence. Yet, although capecitabine he

12 open arms in NCI-MATCH treatment trial await patients with advanced or rare cancers

 E-Mail IMAGE: Dr. O Dwyer is co-leading the largest precision medicine cancer clinical trial to date, NCI-MATCH, with 39 single-arm phase II treatment arms. Researchers are locating patients for the 12 remaining arms. view more  Credit: University of Pennsylvania The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) cancer clinical trial is expanding with the opening of a new treatment arm. The addition, Arm Z1M, is a single-arm phase II study of a two-drug combination, relatlimab and nivolumab, both immunotherapies. To be eligible, patients must have mismatch repair deficiency on genomic testing and tumors that express the LAG-3 protein, a cancer immunotherapy target. The cancer must also have progressed on anti-PD-1/PD-L1 immunotherapy. The addition brings the number of available treatment arms in NCI-MATCH to 12. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), part of the National Institutes of Health, are co-leading

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.